Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

BVAXF Relative to the S&P 500

Seasonal Chart Analysis

Analysis of the BioVaxys Technology Corp. (OTCMKT:BVAXF) seasonal charts above shows that a Buy Date of August 10 and a Sell Date of November 5 has resulted in a geometric average return of 39.64% above the benchmark rate of the S&P 500 Total Return Index over the past 6 years. This seasonal timeframe has shown positive results compared to the benchmark in 6 of those periods. This is an excellent rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 6 years by an average of 69.41% per year.

A word of caution: Only 6 years of data is available for shares of BVAXF, perhaps insufficient to create a seasonal profile that accurately gauges the seasonal tendencies influencing the investment. Ideally, while 20 years is preferred, at least 10 years of data is required to perform a seasonal analysis that is considered to be reliable for future seasonal periods.

BioVaxys Technology Corp. is a clinical stage biotechnology company. It engages in developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The firm is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology and is preparing for a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors that will initially be developed for Stage III/Stage IV ovarian cancer. The company was founded by James Christopher Passin, Kenneth E. Kovan and David Berd on April 25, 2018 and is headquartered in Etobicoke, Canada.

To download BVAXF seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: BVAXF